GO:0009152 purine ribonucleotide biosynthetic process: De Novo Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009152 describes the chemical reactions and pathways that build purine ribonucleotides, the ribose- and phosphate-containing building blocks of RNA and DNA.
• The de novo pathway converts simple precursors such as phosphoribosyl pyrophosphate (PRPP), glycine, glutamine, aspartate, and formyl-THF into inosine monophosphate (IMP) through a conserved ten-step enzymatic cascade.
• Purine biosynthetic enzymes can assemble into liquid-like condensates, and this assembly depends on the chaperone HSP90.
• Purine ribonucleotide biosynthesis is tightly linked to cell growth, inflammation, senescence, and cancer metabolism.
• Enzymes such as PAICS, GART, and ATIC are candidate targets for inhibitor discovery and for CRISPR-based functional studies.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow researchers to dissect the causal role of each purine biosynthetic gene.
Description
Purine ribonucleotide biosynthetic process (GO:0009152) is the biological process that produces purine ribonucleotides, which are ribonucleoside phosphates containing a purine base linked to ribose and esterified with phosphate at the 3' or 5' hydroxyl group of the sugar. These molecules are essential for RNA synthesis, DNA synthesis after reduction to deoxyribonucleotides, energy transfer, and intracellular signaling. The de novo purine biosynthesis pathway is one of the most conserved metabolic routes in life and converts PRPP, glycine, glutamine, aspartate, and one-carbon units into inosine monophosphate (IMP), the first fully formed purine ribonucleotide. Because purine ribonucleotides sit at the intersection of nucleic acid metabolism, energy homeostasis, and signaling, defects or deregulation in this process are associated with human disease. For example, purine release and metabolism shape inflammatory responses, and altered purine biosynthesis contributes to the senescence-associated secretory phenotype in cancer cells. The pathway also has unusual cell biology: several purine biosynthetic enzymes form liquid-like condensates in a manner dependent on HSP90 activity. For researchers, GO:0009152 provides a precise ontology anchor for interpreting transcriptomic, proteomic, and CRISPR screening data. Understanding which enzymes catalyze each step, how the pathway is regulated, and how it can be modeled experimentally is essential for target discovery in oncology, immunology, and metabolic disease.
purine ribonucleotide biosynthetic process At A Glance
| GO ID | GO:0009152 |
|---|---|
| GO term | purine ribonucleotide biosynthetic process |
| Ontology | biological_process |
| Definition | The chemical reactions and pathways resulting in the formation of a purine ribonucleotide, a compound consisting of ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5' hydroxyl group of the sugar. |
| Synonyms | purine ribonucleotide anabolism; purine ribonucleotide biosynthesis; purine ribonucleotide formation; purine ribonucleotide synthesis |
| Major function | Production of purine ribonucleotides such as IMP, AMP, and GMP for RNA, DNA, energy metabolism, and signaling |
| Key pathway | De novo purine biosynthesis from PRPP, glycine, glutamine, aspartate, and formyl-THF |
| Representative enzymes | PPAT, GART, PFAS, PAICS, ADSL, ATIC, IMPDH, GMPS |
| Cellular context | Cytosolic and, in some cases, condensate-associated enzyme assemblies dependent on HSP90 |
What Is GO:0009152?
In plain terms, GO:0009152 describes the set of chemical reactions and pathways that result in the formation of a purine ribonucleotide, a compound consisting of a purine base linked to a ribose sugar and esterified with a phosphate group at either the 3' or 5' hydroxyl group of the sugar. This process includes both the de novo assembly of the purine ring on a ribose-phosphate scaffold and the enzymatic steps that generate the finished ribonucleotide product.
Why Is purine ribonucleotide biosynthetic process Important in Cell Biology?
GO:0009152 matters because purine ribonucleotides are required for nearly every aspect of cellular life, including RNA and DNA synthesis, ATP and GTP energy currency, and nucleotide-based signaling. The de novo pathway is a major metabolic commitment step, and its output must be balanced with salvage pathways and with the demand for nucleotides during proliferation. Because rapidly dividing cells and activated immune cells have high purine demands, this process is a focal point for cancer metabolism, immunology, and anti-proliferative drug discovery.
• Provides the ribonucleotide precursors for RNA synthesis and, after reduction, for DNA synthesis.
• Supplies ATP and GTP, which are central to cellular energy transfer and signal transduction.
• Supports rapid proliferation, making it a metabolic vulnerability in cancer cells.
• Shapes inflammatory responses through purine release, metabolism, and signaling.
• Is linked to the senescence-associated secretory phenotype via PAICS acetylation and ACSS2.
• Involves enzyme assemblies and condensates that depend on HSP90 activity.
• Contains multiple druggable enzymes, including N5-CAIR mutase and other pathway steps.
• Is a frequent hit category in metabolic CRISPR screens and purinome-targeted studies.
• Provides biomarkers and mechanistic hypotheses for hyperuricemia and purine disorders.
• Offers a conserved model system for studying enzyme channeling and metabolon organization.
What Happens During purine ribonucleotide biosynthetic process?
Activation of PRPP and the first committed step
In simple terms: The cell first activates a sugar-phosphate molecule so that it can build a purine ring on top of it.
The de novo purine pathway begins with phosphoribosyl pyrophosphate (PRPP), which is converted by amidophosphoribosyltransferase (PPAT) in the first committed step of the pathway. This step commits the cell to purine biosynthesis and is a key regulatory node. The reaction replaces the pyrophosphate of PRPP with an amino group derived from glutamine, generating 5-phosphoribosylamine and setting the stage for ring assembly.
Assembly of the imidazole ring
In simple terms: The cell builds the first ring of the purine scaffold using glycine and other small molecules.
Subsequent steps incorporate glycine, formyl-THF, and glutamine to build the imidazole portion of the purine ring. GART (phosphoribosylglycinamide formyltransferase) and related enzymes catalyze formylation and amination reactions that progressively decorate the ribose scaffold. These transformations are conserved across species and are essential for generating the intermediate formylglycinamidine ribonucleotide.
Closure of the pyrimidine ring and formation of IMP
In simple terms: The second ring is closed to produce the first complete purine ribonucleotide.
The pathway continues through AIR (aminoimidazole ribotide) and related intermediates, with carboxylation and amination steps that close the second ring. PFAS, PAICS, ADSL, and ATIC catalyze the later steps, ultimately producing inosine monophosphate (IMP), the first fully formed purine ribonucleotide. Carboxylation chemistry in this segment has been studied in detail and is a target for mechanistic and inhibitor research.
Branching to AMP and GMP
In simple terms: IMP is converted into the two main purine ribonucleotides used by cells.
IMP serves as the branch point for AMP and GMP synthesis. IMPDH and GMPS contribute to guanine nucleotide formation, while other enzymes convert IMP toward adenine nucleotides. This branching allows the cell to balance adenine and guanine nucleotide pools according to demand for RNA, DNA, and energy metabolism.
Enzyme organization and condensates
In simple terms: Some purine enzymes cluster together in dynamic droplets inside cells.
Purine biosynthetic enzymes can assemble into liquid-like condensates, and this assembly depends on the activity of the chaperone protein HSP90. This organization may influence pathway efficiency and regulation, and it provides a cell-biological angle for studying GO:0009152 beyond classical enzymology.
Key Genes Involved in GO:0009152 purine ribonucleotide biosynthetic process
The following genes and enzymes are central to purine ribonucleotide biosynthetic process (GO:0009152) and are commonly studied with CRISPR and metabolic assays.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPAT | Catalyzes the first committed step of de novo purine biosynthesis from PRPP | Rate-limiting node; target for pathway flux studies |
| GART | Formyltransferase and related activities in early purine ring assembly | Frequently studied in de novo purine enzymology |
| PFAS | Catalyzes multiple steps in the later de novo pathway | Multifunctional enzyme; candidate for metabolic screens |
| PAICS | Bifunctional enzyme in IMP synthesis; subject to acetylation | Linked to senescence-associated secretory phenotype |
| ADSL | Catalyzes adenylosuccinate lyase step in purine biosynthesis | Relevant to purine pathway flux and disease models |
| ATIC | Bifunctional enzyme in IMP synthesis | Target for structural and inhibitor studies |
| IMPDH | Converts IMP toward guanine nucleotides | Key branch-point enzyme for GMP synthesis |
| GMPS | Catalyzes the final step of GMP synthesis | Relevant to guanine nucleotide pool regulation |
| HSP90 | Chaperone required for purine enzyme condensate assembly | Links proteostasis to purine biosynthesis |
| ACSS2 | Limits purine biosynthesis through PAICS acetylation | Connects acetyl-CoA metabolism to purine flux |
| N5-CAIR mutase | Catalyzes a step in the de novo purine pathway | Structure-guided inhibitor discovery target |
| Purine salvage enzymes | Recycle free purines into ribonucleotides | Balance de novo and salvage flux |
| Adenosine receptors | Mediate purine signaling in inflammation | Connect purine metabolism to immune responses |
| PRPP synthetase | Generates PRPP for de novo and salvage pathways | Upstream regulator of pathway capacity |
| Formyl-THF cycle enzymes | Supply one-carbon units for purine ring formylation | Link one-carbon metabolism to purine biosynthesis |
How Is purine ribonucleotide biosynthetic process Regulated?
Purine ribonucleotide biosynthesis is regulated at multiple levels. The pathway is responsive to cellular demand for nucleotides and is coordinated with one-carbon metabolism, which supplies formyl-THF for ring formylation. Enzyme abundance and activity can be modulated by post-translational modifications; for example, ACSS2 limits purine biosynthesis through PAICS acetylation, linking acetyl-CoA metabolism to pathway output. In addition, the assembly of purine biosynthetic enzymes into liquid-like condensates depends on HSP90 activity, suggesting that proteostasis machinery influences pathway organization. Purine release and signaling also feed back on inflammatory and metabolic states, connecting GO:0009152 to broader physiological regulation.
purine ribonucleotide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAICS | Senescence-associated secretory phenotype and cancer metabolism | Knockout or acetylation-site point mutation in cancer cell lines |
| ACSS2 | Metabolic regulation of purine biosynthesis | Overexpression and knockout models to test pathway flux |
| HSP90 | Proteostasis and purine enzyme condensate assembly | Knockout or tagged knock-in to visualize condensates |
| N5-CAIR mutase | Inhibitor discovery for purine pathway targeting | Enzyme assays and point-mutation models |
| Purine salvage enzymes | Purine metabolism disorders and hyperuricemia | Knockout models to study pathway balance |
Cancer metabolism and senescence
Rapidly proliferating cancer cells have high demand for purine ribonucleotides to support RNA and DNA synthesis. ACSS2 drives the senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation, directly linking GO:0009152 to tumor cell biology and senescence. This makes purine biosynthetic enzymes attractive candidates for metabolic targeting in cancer research.
Inflammation and immune signaling
Purine release, metabolism, and signaling are integral to the inflammatory response. Because purine ribonucleotides are precursors to signaling molecules such as adenosine, changes in GO:0009152 flux can influence immune cell behavior and inflammatory outcomes. This connection supports research into purine pathway enzymes as modulators of inflammation.
Purine metabolism disorders and hyperuricemia
Alterations in purine metabolism can contribute to hyperuricemia and related clinical conditions, as discussed in studies of myogenic hyperuricemia. While GO:0009152 specifically covers biosynthesis of purine ribonucleotides, its balance with degradation and salvage pathways is relevant to uric acid homeostasis and purine-related disorders.
Therapeutic targeting of purine enzymes
Structural and mechanistic studies have identified purine biosynthetic enzymes, such as N5-CAIR mutase, as targets for inhibitor discovery. Targeting the purinome more broadly has been proposed as a strategy for modulating nucleotide-dependent processes in disease. These efforts depend on a precise understanding of GO:0009152 and its enzymatic steps.
From purine ribonucleotide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a purine biosynthetic gene essential for proliferation? | CRISPR knockout in cancer cell lines |
| Does a specific catalytic residue control pathway flux? | Point-mutation knock-in of the enzyme active site |
| How does a disease-associated variant affect purine biosynthesis? | Knock-in of the variant allele with metabolic readouts |
| Where and when is a purine enzyme expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a pathway enzyme increase nucleotide pools? | Overexpression cell model with metabolomics |
| Which genes modify sensitivity to purine pathway inhibition? | CRISPR library screening and bioinformatics |
How to Study the purine ribonucleotide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Targeted metabolomics | Levels of purine ribonucleotides and intermediates | Pathway flux and pool size analysis |
| Stable isotope tracing | Flux through de novo purine biosynthesis | Mechanistic studies of GO:0009152 |
| Enzyme activity assay | Catalytic activity of purine biosynthetic enzymes | Inhibitor testing and mutant characterization |
| Structural biology | Enzyme-substrate interactions and mechanism | Structure-guided inhibitor discovery |
| Fluorescence imaging | Formation of enzyme condensates | Study of HSP90-dependent assembly |
| CRISPR knockout screening | Gene essentiality and pathway dependencies | Target discovery in cancer and metabolism |
| RNA-seq | Expression of purine biosynthetic genes | Pathway regulation and stress responses |
| Proteomics | Protein abundance and modifications | Post-translational regulation such as acetylation |
Metabolomics and flux analysis
Mass spectrometry-based metabolomics can quantify purine ribonucleotide pools and intermediates such as IMP, AMP, and GMP. Stable isotope tracing allows researchers to measure flux through GO:0009152 and to determine how genetic perturbations alter pathway activity.
Enzyme assays and structural biology
Purified enzymes can be assayed for catalytic activity, and structural studies can reveal substrate binding and mechanism. Carboxylation steps in de novo purine biosynthesis have been studied with specialized methods, and structure-guided inhibitor discovery has targeted enzymes such as N5-CAIR mutase.
Imaging of enzyme condensates
Fluorescence microscopy of tagged purine biosynthetic enzymes can reveal liquid-like condensates and their dependence on HSP90 activity. This approach connects GO:0009152 to cell biology and proteostasis research.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens can identify genes that modify purine pathway dependence or drug sensitivity. Bioinformatics analysis of screening data, combined with pathway annotation such as GO:0009152, helps prioritize candidate targets for follow-up.
How CRISPR Can Be Used to Study GO:0009152 purine ribonucleotide biosynthetic process
Knockout
CRISPR knockout of purine biosynthetic genes such as PAICS or PPAT can test whether they are required for proliferation or survival in a given cell model. Knockout studies help establish causal roles for GO:0009152 enzymes in cancer metabolism and inflammation.
Point Mutation
Point-mutation models can be used to dissect catalytic residues or regulatory modification sites, such as acetylation sites on PAICS. These models allow researchers to separate enzymatic activity from other functions of a protein.
Knock-in
Knock-in of disease-associated variants or tagged alleles enables precise studies of how specific sequence changes affect purine ribonucleotide biosynthesis. Tagged knock-in can also support imaging of enzyme localization and condensate formation.
Overexpression
Overexpression models can test whether increasing a purine biosynthetic enzyme raises nucleotide pools or alters pathway flux. Such models are useful for studying rate-limiting steps and for validating metabolic hypotheses.
How EDITGENE Supports purine ribonucleotide biosynthetic process Research
Researchers studying purine ribonucleotide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway output, disease phenotypes, or drug response. CRISPR-based models provide a rigorous way to move from correlation to causation, and EDITGENE offers end-to-end services to generate and characterize these models.
Contact EDITGENE today to design your custom CRISPR model for purine ribonucleotide biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID |
|---|
Frequently Asked Questions About purine ribonucleotide biosynthetic process
What is GO:0009152 purine ribonucleotide biosynthetic process?
GO:0009152 is a Gene Ontology biological process term describing the chemical reactions and pathways that form purine ribonucleotides, which are purine bases linked to ribose and phosphate groups.
What genes are involved in purine ribonucleotide biosynthetic process?
Key genes include PPAT, GART, PFAS, PAICS, ADSL, ATIC, IMPDH, and GMPS, which catalyze steps in de novo purine biosynthesis.
Why is purine ribonucleotide biosynthesis important for cancer?
Cancer cells require purine ribonucleotides for rapid proliferation, and pathways such as PAICS acetylation can influence senescence and secretory phenotypes.
How is purine ribonucleotide biosynthesis regulated?
It is regulated by metabolic demand, one-carbon supply, post-translational modifications such as PAICS acetylation, and HSP90-dependent enzyme condensate assembly.
What is the first committed step of purine biosynthesis?
The first committed step is catalyzed by PPAT, which converts PRPP into 5-phosphoribosylamine.
What is IMP in purine biosynthesis?
IMP, or inosine monophosphate, is the first fully formed purine ribonucleotide and the branch point for AMP and GMP synthesis.
Can CRISPR be used to study purine ribonucleotide biosynthetic process?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test the causal roles of purine pathway genes.
What methods measure purine ribonucleotide biosynthesis?
Targeted metabolomics, stable isotope tracing, enzyme assays, imaging, and CRISPR screens are commonly used to study this pathway.
Which diseases are linked to purine metabolism?
Purine metabolism has been linked to hyperuricemia, inflammatory responses, and cancer metabolism.
How does HSP90 affect purine biosynthesis?
HSP90 activity is required for purine biosynthetic enzymes to assemble into liquid-like condensates.
Conclusion
GO:0009152 purine ribonucleotide biosynthetic process is a central metabolic pathway that supplies the ribonucleotide building blocks for RNA, DNA, energy metabolism, and signaling. Its enzymes are conserved, regulated at multiple levels, and increasingly recognized as targets in cancer, inflammation, and purine-related disorders. By combining CRISPR knockout, point-mutation, knock-in, overexpression, and library screening approaches with metabolomics and imaging, researchers can dissect how each gene contributes to pathway output and disease phenotypes. EDITGENE provides the tools and services needed to build these models and to accelerate functional studies of purine ribonucleotide biosynthesis.
References
- 1. Pareek V et al.. 2021. Human de novo purine biosynthesis.. Crit Rev Biochem Mol Biol 56(1):1-16 PMID: 33179964
- 2. Linden J et al.. 2019. Purine Release, Metabolism, and Signaling in the Inflammatory Response.. Annu Rev Immunol 37:325-347 PMID: 30676821
- 3. Yang L et al.. 2025. ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation.. Nat Commun 16(1):2071 PMID: 40021646
- 4. Pedley AM et al.. 2022. Purine biosynthetic enzymes assemble into liquid-like condensates dependent on the activity of chaperone protein HSP90.. J Biol Chem 298(5):101845 PMID: 35307352
- 5. Sharma MF et al.. 2024. Carboxylation in de novo purine biosynthesis.. Methods Enzymol 708:389-424 PMID: 39572148
- 6. Yamasaki T et al.. 1996. [Myogenic hyperuricemia].. Nihon Rinsho 54(12):3343-8 PMID: 8976117
- 7. Belfon KKJ et al.. 2023. Structure-Guided Discovery of N(5)-CAIR Mutase Inhibitors.. Biochemistry 62(17):2587-2596 PMID: 37552766
- 8. Murray JM et al.. 2009. Targeting the purinome.. Methods Mol Biol 575:47-92 PMID: 19727611
